Cygnus distributor void
This article was originally published in The Gray Sheet
Executive Summary
GlucoWatch G2 Biographer manufacturer "does not expect any significant product revenues in 2004 unless it secures a sales, marketing and distribution partner or other strategic alliance," the company reports in a March 26 release announcing 2003 financial results. The firm has been without a distributor since the dissolution of a marketing deal with Sankyo Pharma in December. Mainly due to the $75.8 mil Sankyo settlement, 2003 net income was $49.3 mil., up from a $41.7 mil. loss in 2002. However, revenue fell $1 mil. to $2.9 mil., and income from NIH Small Business Innovation Research grants was down to $234,000 from $401,000 in 2002...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.